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Adegbenro Omotuyi John Fakoya*
Department of Anatomical Sciences, All Saints University School of Medicine, Roseau, Dominica
The finances of patients and countries are increasingly overwhelmed with the plague 
of cardiovascular diseases as a result of having to chronically manage the associated 
complications of ischemia such as heart failures, neurological deficits, chronic limb 
ulcers, gangrenes, and amputations. Hence, scientific research has sought for alternate 
therapies since pharmacological and surgical treatments have fallen below expectations 
in providing the desired quality of life. The advent of stem cells research has raised 
expectations with respect to vascular regeneration and tissue remodeling, hence assuring 
the patients of the possibility of an improved quality of life. However, these supposed 
encouraging results have been short-lived as the retention, survival, and engraftment 
rates of these cells appear to be inadequate; hence, the long-term beneficial effects of 
these cells cannot be ascertained. These drawbacks have led to the relentless research 
into better ways to deliver stem cells or angiogenic factors (which mobilize stem cells) 
to the regions of interest to facilitate increased retention, survival, engraftment, and 
regeneration. This review considered methods, such as the use of scaffolds, retrograde 
coronary delivery, improved combinations, stem cell pretreatment, preconditioning, 
stem cell exosomes, mannitol, magnet, and ultrasound-enhanced delivery, homing 
techniques, and stem cell modulation. Furthermore, the study appraised the possibility 
of a combination therapy of stem cells and macrophages, considering the enormous 
role macrophages play in repair, remodeling, and angiogenesis.
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iNTRODUCTiON
Ischemia is a partial or complete interruption of blood supply to a tissue or organ with an 
accompanying interruption of the flow of oxygen, glucose, and tissue washout resulting in 
tissue death by necrosis. Most pertinent to the medical practice are cardiovascular diseases 
(CVDs), a disease of the heart and blood vessels of which myocardial infarction (MI), stroke, 
and peripheral arterial diseases (PAD) is the most notable. More than 27 million Americans 
(1) and 202 million people worldwide (2) have experienced an ischemic heart event, stroke, or 
hospitalization for heart failure, peripheral arterial disease with smoking, increasing age, and 
diabetes being major risk factors (2). The American Heart Association estimates the annual cost 
of CVD to be $155 billion in direct health-care costs and another $92 billion in indirect costs 
reflecting lost productivity (3). CVDs, mainly acute MI, caused by the occlusion of the coronary 
arteries are the leading cause of mortality worldwide (4, 5). CVD usually damages the heart 
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muscle cells [cardiomyocytes (CMCs)] irreversibly resulting 
in complications associated with MI such as early mortality 
occurring from arrhythmias such as ventricular tachycardias 
and fibrillations (6, 7). CMCs have previously been regarded 
as post-mitotic cells; however, increasing research evidence has 
disproved this with observations revealing that ischemic events 
may influence the proliferative capacity of adult mammalian 
CMCs (8), though young adult CMCs have an annual renewal 
rate of about 1% (9). The world heart federation, 2016, stated 
that stroke which occurs as a result of the loss of blood sup-
ply to the brain is the seconding leading cause of mortality 
over 60  years of age and the fifth between the ages of 15 and 
59 years resulting in a long-term neurological deficit. Another 
debilitating ischemia is that of the lower limb, which may lead 
to gangrene and ultimately amputation of the affected limb. 
Lower limb ischemia can either be an acute (as a result of an 
arterial embolism) or a critical limb ischemia (which is an 
end-stage result of a PAD) affecting about 2 million Americans 
(1, 10). Atherosclerosis, an inflammatory disease, is the pri-
mary pathophysiology underlying CVDs in which endothelial 
dysfunction is a critical initial event in its pathogenesis, and 
this contributes to the initiation and progression of plaque (11, 
12). Research has been carried out on diverse stem cells with 
rather promising results. However, quite a few challenges still 
need to be overcome, such as identifying the most appropriate 
mode of delivery, timing of delivery, survival, retention, and 
integration of these therapeutic cells to the site of ischemia with 
enhancement of revascularization and angiogenesis. The goal of 
a delivery system is to be able to transplant the right amount 
of (stem) cells to the site of interest and attain the maximal cell 
retention and ultimately prevent the deleterious effect of the 
ischemia such as amputation, heart failure, and neurological 
deficits. Thus, this study examined previous methods of stem 
cell delivery and the new methods being used to deliver stem 
cells for an efficient vascular regeneration.
MeTHODS
Data for this study were obtained from Medline on OvidSP, 
which includes PubMed, Embase by the US National Library 
of Medicine as well as a search through the University of Bristol 
Library services.
Search Strategy
The search was carried out by signing into Ovid, Wolters, and 
Kluver portal and “All Resources” was selected. The keyword 
“stem cell delivery” was used with a further selection made on 
stem cell transplantation. So search for stem cell delivery/stem 
cell transplantation gave a total number of 19,919 publications. 
The second search with the keyword “ischemia/tissue ischemia” 
yielded a total number of 46,597 articles.
Combining the search for “stem cell delivery/stem cell trans-
plantation” using the Boolean operator “AND” with “ischemia/
tissue ischemia” yielded a total of 274 publications. Publications 
were then further hand screened to ascertain if they fit into 
the inclusion the criteria for the study and I arrived at a total 
of about 66.
However, other data included in the release were obtained 
from the University library services by simply using the search 
phrase “stem cell delivery” and “stem cells in ischemia” and articles 
around vasculogenesis/angiogenesis and were hand screened to 
fit the inclusion criteria and 38 other publications were selected. 
Also included were relevant references from previously selected 
articles as well as some recommended publications. A total of 171 
articles were reviewed.
inclusion Criteria
Publications selected were analyzed thoroughly to see if they 
focused on the study which was on delivery of stem cells in the 
setting of ischemia. Included were studies that utilized stem cells 
(such as embryonic, mesenchymal, adult, endothelial progeni-
tor, cardiac, hematopoietic, and induced pluripotent stem cells) 
in the setting of ischemia such as myocardial ischemia, limb 
ischemia, and cerebral ischemia. Also considered were publi-
cations which included scaffolds in the delivery of stem cells 
and new modes of targeting and delivering stem cells to sites of 
ischemia and articles that also considered tracking of these cells 
to target sites.
BRieF OveRview OF THe MOLeCULAR 
BASiS OF BLOOD veSSeL FORMATiON
Vasculogenesis and angiogenesis are the two methods for blood 
vessel formation. The formation of primordial blood vessels is 
known as vasculogenesis, and this occurs during embryogenesis 
as a result of increasing metabolic and oxygen demands of the 
organs of the embryo as their sizes increases. Four major steps 
are involved in this, and this includes (i) mesoderm formation, 
(ii) differentiation into blood islands, (iii) blood island fusion, 
and (iv) primary capillary plexus formation. Nevertheless, new 
sites of vascularizations have been demonstrated in adults as 
well (13). Angiogenesis, however, is the formation of new blood 
vessels from previously existing ones, and two processes are 
involved in this (i) budding/sprouting, this is the growth phase, 
where stabilization of new blood vessels occurs and (ii) intus-
susception, here the local vascular network is remodeled by the 
insertion of interstitial cells which helps to partition the new 
vessels (14).
Vasculogenesis is initiated in the embryo by the fibroblast 
growth factor (FGF) ligand/receptor system inducing the 
mesoderm to form blood islands. The endoderm then releases 
the vascular endothelial growth factor (VEGF) following 
the expression of its receptors VEGF-R2 (Flk-1) and SCL/
TAL-1 by haemangioblasts thus facilitating its differentiation 
into hematopoietic and endothelial cell (EC) lines. Another 
receptor, VEGF-R1 (Flt-1) is also released but however utilized 
late in angiogenesis to promote aggregation of angioblasts. 
VEGF facilitates differentiation into ECs, while platelet-derived 
growth factor (PDGF)-BB induces smooth muscle (SMC) 
formation and is mitogen and for both SMCs and pericytes. 
Angiopoietin (Ang-1), a Tie-1(tek) ligand enhances luminal 
formation and stabilization, while Ang-2 halts the process. 
EC proliferation is then enhanced by PDGF-BB bound to 
FiGURe 1 | Summary of vasculogenesis and angiogenesis with some molecular overview.
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receptor PDGFBR and transforming growth factor (TGF)-B1 
antagonizes this by facilitating the contact between ECs and 
pericytes (14). Other factors involved in adhesion of ECs and 
junction formation include endothelial transcriptase (ets)-1, 
platelet endothelial cell adhesion molecule (PECAM)-1 
(CD31), vascular endothelial-cadherin, and CD34 (15). 
Figure  1 below shows the schematic representation of the 
process of vasculogenes.
Angiogenesis on the hand involves (i) migration of ECs, (ii) 
tubulogenesis, (iii) vessel maturation, and (iv) vessel stabiliza-
tion. The expression of either VEGF or hepatocyte growth factor 
(HGF), which initiates angiogenesis facilitates this process by 
subtly different mechanisms.
Vascular endothelial growth factor, when expressed, increases 
the permeability of vessels causing the release of fibrinogen which 
triggers coagulation. Coagulation and fibrinolysis are regulated 
by tissue plasminogen activator (tPA) and urokinase-type plas-
minogen activator (uPA), respectively, with plasminogen activa-
tor inhibitor-1 inhibiting both and favoring the EC detachment 
from the matrix (16). Clots are dissolved by plasmin which also 
activates metalloproteinases (MMP), the binding of MMPs to the 
protein Vitronectin (facilitates binding to αvβ3) stabilizes it. The 
secreted MMPs encourage the breakdown of the basal lamina 
by the EC and then its matrix. While collagen type 1 is being 
degraded by the MMPs, the RGD (Arginine–Glycine–Aspartate) 
sequences are exposed enhancing its binding to αvβ3 integrin. 
FiGURe 3 | Redrawn from Ref. (19, 20).
FiGURe 2 | eCM modification with the degradation of the basement membrane during angiogenesis.
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The formation of a new basal lamina which blocks the contact 
between the EC and collagen type 1 stops the progression. bFGF 
and VEGF/protein kinase C induce the integrins αvβ3 and αvβ5, 
respectively (16).
After the formation of these vessels, there is the need to deter-
mine their arterial-venous identity. Notch ligand and receptors 
are regulators of cell fate, while regulators of arterial fate include 
VEGF and Ephrin B2 with Ephrin B4 and Coup-TFII being 
venous cell fate regulators (17).
Overall, a couple of factors help to halt the angiogenic process, 
and these include tissue inhibitors of MMPs (TIMP), cytokines 
such as IL-4, IL-10, IL-12, thrombospondins-1 and 2, MMP2 
c-terminal lytic fragments. Other angiostatic agents include 
endostatin, angiostatin, maspin, and TGFβ (16). See Figure 2.
Hepatocyte growth factor considered the angiogenic factor 
with the most potency affects both the ECs and SMCs. The 
binding of HGF to its C-met receptor activates Ets-1, which then 
facilitates the expression of the factors necessary for angiogenesis 
and regeneration (18). Figure 3 below summarizes the event.
However, during ischemic/hypoxic states, the expression of 
hypoxia-inducible factor (HIF)-1 is induced. HIF is a transcrip-
tion factor which encodes for the angiogenic cytokines. It has 
two subunits: the alpha is regulated by oxygen while the beta 
is constitutively expressed (21). These angiogenic cytokines 
with their respective receptors include VEGF/VEGFR1, pla-
cental growth factor/VEGFR2, stromal-derived factor (SDF)-1/
chemokine receptor 4 (CXCR4) (22). In muscle ischemia, for 
instance, there is an elaboration of a higher than normal SDF-1, 
which facilitates the mobilization of hematopoietic stem cells 
(HSCs) from the bone marrow niche to the peripheral circula-
tion. The stem cells are recruited to the site of ischemia where 
the ligands SDF-1, stem cell factor, and fibronectin are bound 
by their respective receptors CXCR4, C-Kit, and α-4 integrin on 
the stem cells.
In tissue hypoxia, the elaborate intracellular oxygen sensor 
proteins, the protein hydroxylase domain-containing proteins 
1-3, and the HIF-1 and 2 analyze cellular oxygen content and 
induce a response to counteract the deficient oxygen supply (23). 
The abundance of HIF is not solely controlled by PHDs but also 
by nitric oxide (NO) even in normoxic conditions. NO influences 
the accumulation of HIF-1a protein by preventing its degradation 
independent of gene transcription and translation (24). VEGF 
is induced in an HIF-1a dependent manner during EC hypoxia 
and HIF-1a and 2a cannot be substituted for one another as they 
perform distinct roles in angiogenesis (23).
Nitric oxide, similar to VEGF, is a potent angiogenic and 
vascular permeability factor which plays a vital function in both 
physiological and pathological angiogenesis (25). Three isoforms 
of NO synthase exists, which are neuronal NOS, inducible 
NOS (iNOS), and endothelial NOS (eNOS). VEGF enhances 
NO synthesis and likewise induces the expression of iNOS and 
eNOS (expressed constitutively in vascular endothelial cells) 
(23). Thus the assumption that vascular EC eNOS synthesizes 
NO in response to VEGF, and this NO mediates the increased 
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vascular permeability and angiogenesis induced by VEGF. NO 
synthesized by iNOS also mediates both vascular permeability 
and angiogenesis, however to a lesser degree than eNOS (23). The 
NO enhanced angiogenesis may be more of pathological such as 
in solid tumors than the physiological angiogenesis which occurs 
in development and vasculogenesis.
Other angiogenesis enhancing factors (mobilizers) include 
erythropoietin, granulocyte colony stimulating factor, statins, 
estrogen, exercise, and peroxisome proliferator-activated recep-
tor (PPARγ), and these utilize ECs or endothelial progenitor 
cells (EPC) from circulation, bone marrow, or exogenously 
administered.
This molecular background drives the diverse studies and 
therapeutic approaches used in the field of stem cells and regen-
eration, and this knowledge is fundamental and is key to the 
understanding of this review.
STeM CeLLS iN iSCHeMiA
Several treatment lines are available for patients with CVDs espe-
cially those who might have suffered an MI. These ranges from 
aspirin to nitroglycerin, B-blockers, and anticoagulants. However, 
those with occlusive symptoms are subjects for immediate rep-
erfusion therapies with thrombolytics/percutaneous coronary 
intervention, commonly called coronary angioplasty. Coronary 
bypass graft surgery (CABG) is usually done when all reperfusion 
therapies have failed. Though these procedures undeniably have 
saved a lot of lives, the quality of life somewhat is still not optimal, 
especially in the case of an MI with a resulting permanent damage 
(Scar). On the other hand, for limb ischemias, drug-eluting stents/
drug-coated balloons in femoral and popliteal arterial segments, 
others include adventitial anti-inflammatory therapy, stimulation 
of the spinal cord, and intermittent air(pneumatic) compression.
Also, several clinical trials using angiogenic factors like VEGF, 
FGF, HGF have bene tried on patients with not so encouraging 
results (26). Thus, the enormous clinical burden posed by CVDs 
have immensely stimulated directions toward gene and cellular 
therapies (27). Stem cells or progenitor cells have been proven 
to have the potentials to differentiate into any tissue type in the 
body including the cardiovascular system (such as endothelial 
cells, smooth muscles, and CMCs). With this potential, we see 
stem cells not just being able to repair or regenerate tissues but 
also facilitate revascularization.
Stem Cells Utilized in ischemic Models
Several studies have been carried out in animals using diverse 
populations of (stem) cells for the treatment of CVDs and hind 
limb ischemias. These includes embryonic stem cells (ESC) 
(28, 29), mesenchymal stem cells (MSC) (30, 31), bone marrow 
mononuclear cells (BMMNC) (32, 33), endothelial progenitor 
cells (EPC) (34, 35), mature ECs (34), marrow-derived stromal 
cells (36), peritoneal macrophages (37), polarized macrophages 
(38), adipose tissue-derived stem cells (39), autologous cultured 
adipose-derived stem cells (40), saphenous vein progenitors 
(SVPs) (41), pericytes (42).
Despite the benefits of these stem cells, tumor formation and 
immune intolerance have been a major drawback to their use. 
Among others, MSCs are considered one of the main and the 
most attractive sources for stem cell therapy for reasons such 
as low tumorigenic potentials (43, 44), ease of access as well as 
minimal immunogenicity (45). Also, ESCs are quite immune 
privileged but they may trigger some inflammation via their 
derivatives (46).
Overall, most researchers believe that the benefits derived from 
stem cells do not occur through the transdifferentiation of stem 
cells but rather from their paracrine functions which include the 
release of cytokines and growth factors (47–49).
STeM CeLLS DeLiveRY, ReSULTS, AND 
DiSCUSSiON
Stem cells have been transplanted or administered in the set-
ting of ischemia through various routes. In the case of an MI 
from the clinical point of view, these have been through routes 
such as (i) transvenous infusion, (ii) intracoronary arterial 
infusion, (iii) direct intramyocardial injection with CABG, (iv) 
trans-endocardial injection using catheter, and (v) mobilization 
of stem cells. Zhou and colleagues documented the routes for 
the administration of stem cells in critical limb ischemia, these 
are the intra-arterial, intramuscular, or the combination of 
both. For an MI, the two most utilized methods are CABG with 
intramyocardial injection and the intracoronary infusion, while 
the intramuscular injection is the most preferred method during 
limb ischemia (50).
The transvenous route, though an easy approach for stem cell 
delivery in myocardial injury, relies majorly on a successful hom-
ing process and stem cell retention (51).
The intracoronary route of delivery encourages the homog-
enous administration of a maximum number of cells to the dam-
aged site. However, the non-perfused areas do not benefit (52).
Direct intramyocardial injection is the most preferred method 
of delivery, particularly for patients with chronic heart failure 
(53). However, necrosed tissues are oxygen and nutrient deprived, 
and injected cells would not have healthy cardiac cells to provide 
paracrine support, hence a reduction in differentiation and graft 
survival (50).
The Table 1 below shows the advantages and limitations of the 
methods of delivery stem cells.
Researchers have investigated best possible methods for stem 
cells delivery which will result in a successful neovascularization. 
The goal is ensuring a successful homing of the cells to regions 
of ischemia, prolonging survival, and retention of these cells, as 
less than 10% of cells are retained after 24 h and only about 1% 
after 4 weeks (54). Furthermore, methods that non-invasive are 
being considered because of the hazards associated with operative 
procedures. Taking stroke as a case study, injecting neural stem 
cells or mesenchymal cells directly into the lesioned brain might 
yield a remarkable result, but the use of a non-invasive technique 
could be used to avoid the associated operative hazards.
The new methods which have been used for the delivery of 
stem cells include
(a) Scaffolds
(b) Retrograde delivery
TABLe 1 | Advantages and limitations of routes of delivery.
Delivery method Advantages Limitations
Intracoronary artery 
infusion
Direct infusion 
infarct-related 
coronary artery 
cell engraftment 
homogenously at 
infarct borders
Not applicable to occluded artery. 
Possible micro embolism during 
infusion
Surgical 
intramyocardial 
injection
Smaller number of 
cells required direct 
inspection
Increased risk of morbidity and 
mortality. Potential induction of 
arrhythmia. Need for a surgical 
approach
Transendocardial 
injection
Cell delivery in 
occluded areas
The risk of myocardial perforation. 
Cardiac tamponade and 
ventricular arrhythmia
Transvenous infusion Non-invasive
Simple delivery
Possible micro embolism
Low cellular migration and 
differentiation. Homing to non-
cardiac organs
Adapted from Ref. (50).
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(c) Improved combinatorial approaches
(d) Stem cell priming or pretreatment
(e) Preconditioning
(f) Stem cell Exosomes
(g) Magnetic enhancement techniques
(h) Ultrasound (US) techniques using (a) microbubble destruc-
tion and (b) acoustic radiation force
(i) Enhanced homing technique
(j) Stem cell modulation techniques
(k) Mannitol-enhanced delivery
Scaffolds in Stem Cell Delivery
Scaffolds are biological materials, which act as a template for 
tissue regeneration and thus guide the growth and formation of 
the new tissue. The use of scaffolds has been extremely useful 
in regenerative medicine in that it permits the combination of 
regenerative cells and angiogenic growth factors as well as allow-
ing control of the cell microenvironment as well increasing cell 
survival and retention within the ischemic host milieu.
Matrigel
The encapsulation of cells enhances the formation of multicellular 
aggregates and also prevents in vivo migration of cells (55). hESC-
ECs encapsulated in Matrigel (enMA-hESC-ECs) have been 
demonstrated to be superior to hESC-ECs alone in the treatment 
of limb ischemia as it permits use without direct incorporation 
enhancing sustained release of various growth factors like VEGF, 
GM-CSF, IL-6, and IL-8 thus exerting its functional potential 
through a paracrine effect (29). The encapsulation could also 
help to overcome the major side effects of transplantation such as 
teratoma formation and tumors (55).
Cardiogel
Cardiogel is a biodegradable 3-D cardiac fibroblast-derived 
extracellular nano-matrix scaffold (56) with a lot of therapeutic 
potentials for cardiac tissue ischemia. Cardiogel has been shown 
to support adhesion, differentiation, and proliferation of stem 
cells (BMSCs) as well as providing increased protection against 
oxidative stress when compared to Matrigel (57). Cells have 
been shown to adhere firmly and resist dislodgement even with 
trypsinization hence preventing flow off to redundant regions of 
the delivered cells (57).
Hydrogels
This biomaterial is very attractive as a scaffold because of its 
similarity to extracellular matrix and under rather mild condi-
tions can be processed. Its delivery is minimally invasive, and its 
degradation can be designed in a timely way to coincide with the 
process of angiogenesis (58). Different hydrogel matrices, either 
natural or synthetic, have been employed as carriers for delivery 
of cells or growth factors. Naturally occurring molecules that can 
be utilized include, collagen, fibrin, gelatin, and hyaluronan, algi-
nate, chitosan which are polysaccharides. The synthetic hydrogels 
include poly (lactic-co-glycolic acid) (PLGA) and polyethylene 
glycol (PEG).
Collagen
Less definite matrices, like collagen, were used in the past to 
provide support for locally injected cells with the restoration of 
vascular networks (59). These matrices, however, did not provide 
the needed controlled release of specific growth factors for clini-
cal applications.
However, this downside has seen improvement over the 
years. For instance, Matsuse et al. (60) designed a combinatorial 
delivery system using collagen sponge as a matrix for the trans-
planted neural stem cell (61). Also, it has been combined with 
gelatin microspheres to enhance the period of vascularization by 
the gradual release of bFGF. Likewise, to strengthen the use of 
collagen materials in regeneration, Shi et al. (62) combined three 
different types of collagen materials in the regeneration of cardiac 
tissue (demineralized bone matrix collagen scaffolds, collagen 
gels, and collagen membranes).
Fibrin
The traditional way of using fibrin for delivery is a physical 
mixture of the factors with thrombin and fibrinogen during the 
process of coagulation (63), however, using this method results 
in an uncontrolled release kinetic of the angiogenic factors VEGF 
and bFGF, usually within 24 h (64). New approaches developed to 
overcome this include covalently linking fibrin to growth factor 
by factor XIIIa transglutaminase activity during coagulation (65). 
Another is the use of the engineered variant of VEGF121 (α2-PII-
8-VEGF121), which attaches itself to fibrin during the coagula-
tion process and this prolongs VEGF expression and retention 
within the fibrin matrix (65). Jeon et  al. in their mouse limb 
ischemic model study, BMMNC and bFGF were transplanted 
using fibrin as a scaffold. Fibrin was shown to increase density 
and survival of transplanted cells (32) as the attachment of cells 
to matrix enhances survival (66, 67). Despite the benefits, fibrin 
has its drawback which is its structural weakness with regards 
to withstanding the dynamic nature of the in vivo physiological 
environment, hence the need for the introduction of synthetic 
biomaterials (PEG, PLGA).
7Fakoya Stem Cells Delivery in Ischemia
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PEG and PLGA
PEGylated hydrogels are designed to be biodegradable in 
response to tissue proteases. The combination of MSCs and 
ECs with PEG hydrogels resulted in the formation of extensive 
tubule-like structures and the differentiation of MSCs further 
enhanced its stability into SMC lineage (68). PEGylated fibrin 
hydrogels were used in a mouse model of MI to deliver MSCs 
because of the drawback of fibrin (69), and this demonstrated a 
15-fold cell retention. Also, there was a substantial reduction of 
apoptosis within and around the scar region and the resulting 
vascularization led to a significant improvement in the contractile 
function of the heart.
Poly (lactic-co-glycolic acid) hydrogels also have been used 
to allow a controlled release of angiogenic factors like VEGF 
and pre-encapsulated PDGF (70) but without protection in the 
tissue environment. The PLGA microparticles, an injectable 
scaffold was designed for the benefit of a prolonged release 
over months and the choice of polymers with varying release 
profiles spanning from 1 week to a couple of months controls 
its gradual degradation into non-toxic products (71). Saif et al., 
in their study, compared a dual (HGF and VEGF) to a triple 
(HGF, VEGF, and Ang-1) combination of pro-angiogenic fac-
tors in a mouse model of hind limb ischemia. This study was 
able to demonstrate how Ang-1 helps in the stabilization of 
newly formed vessels over VEGF. Thus, more vessel formation 
was induced with the triple combination when compared to the 
dual therapy (71).
Hyaluronic Acid (HA) and Heparin
Hyaluronic acid, a glycosaminoglycan with its angiogenic effect 
dependent on its molecular weights. The high molecular HAs 
inhibit angiogenesis, while the low HAs enhanced the prolif-
eration and migration of endothelial cells (72, 73). HA can be 
chemically modified to create a hydrogel that is biocompatible 
with macropores that retain and release angiogenic growth fac-
tors in vivo (74, 75). On the other hand, heparin incorporation 
into hydrogel helps to sequester growth factors thereby slowing 
down their release while still retaining their bioactivity. Heparin 
stabilizes the growth factors preventing its degradation by ECM 
proteinases (76, 77).
Pike et al. designed a hydrogel of HA and gelatin conjugated 
with growth factors VEGF and bFGF and demonstrated that 
incorporation of heparin resulted in an extended release of the 
growth factors, while the in vivo bioactivity of the growth factors 
was maintained (78).
StarPEG-Heparin
StarPEG-heparin is a biohybrid hydrogel which is composed of 
a star-shaped (multi-armed) poly (ethylene glycol) which is the 
“starPEG” coupled with heparin (79). This hydrogel can serve as 
a reservoir and an adaptable release system for heparin-binding 
factors (VEGF and FGF-2); thus, it is an ideal material for a multi-
factorial delivery system (80). Likewise, this hydrogel was shown 
to be suitable for the culture of human umbilical vein endothelial 
cells, and by adjusting the physiochemical structure of the hydro-
gel independent of the biomolecular functionalization, the EC 
behavior such as morphology, proliferation, and survival could be 
modified (80). Likewise, the attractant for EPCs, the angiogenic 
protein SDF 1 alpha (SDF-1α) have functionalized StarPEG-
heparin, and by the incorporation of varying concentrations of 
MMPs, controlled cleavage, and release of varying amounts of 
SDF-1α can be achieved (81).
Alginate
These type of hydrogels have been used to encapsulate angio-
genic growth factors VEGF and bFGF (82), hence comparing 
their angiogenic capacities (83). Neovascularization has been 
promoted using alginate hydrogels by the localized and sustained 
delivery of VEGF and bFGF, but a low dose angiogenic signal 
delivery is essential for the production of a functional vasculature 
because unregulated hemangioma formation may be a side effect 
of VEGF and bFGF overdose or vascular leakage that results in 
edema (58).
Heparinized alginate has been introduced to overcome the 
initial burst release of growth factors, and the ensuing sustained 
release of bFGF, for instance, has been shown to treat porcine 
with MI (84) effectively. More recently, alginate-sulfate-hydrogels 
(a modified alginate hydrogel) was conjugated to HGF in a rabbit 
model of hind limb ischemia, which resulted in considerable 
neovascularization (85).
Further modifications include the RGD (Arg–Gly–Asp) 
modified alginate gel, which has been shown to improve the 
attachment and growth of MSC, also facilitated angiogenic growth 
factor expression. MSCs encapsulated in RGD modified alginate 
gels promoted repair of the heart muscle with angiogenesis by 
improved cell survival in an ischemic environment (86).
Poly-l-Lactic Acid (PLLA)
Poly-l-lactic acid has equally been coupled to RGD to form 
RGD-g-PLLA synthetic scaffold. These three have been shown 
to be good for EPC-targeted delivery in  vivo as it was proven 
to promote vessel regeneration in mouse models for dermal 
wound (87). However, this scaffold was limited by the fact that it 
appeared to degrade rather slowly. As established, the success of 
transplanted cells is largely dependent on the adequate and timely 
degradation of the scaffold which is necessary for the migration 
of the delivered stem cells (87).
Polyvinylidene Fluoride-Tetrafluoroethylene  
(PVDF-TrFE) Scaffolds
The piezoelectric scaffold, electrospun PVDF, and PVDF-TrFE 
have recently been produced for tissue engineering purposes. 
This scaffold has proven to be attractive for cardiovascular tissue 
engineering since the heart is an electroactive tissue (88).
The PVDF-TrFE scaffolds as studied by Pamela et al. revealed 
that they supported the attachment of and survival of embryonic 
stem cell CMCs (mES-CM) and endothelial cells (mES-EC) 
and they both expressed classical endothelial markers such as 
PECAM1, eNOS, and TM on the scaffolds. The scaffold also 
supported the contractile action of mES-CM, while it displayed 
a higher expression of Notch1 an arterial marker suggesting that 
it may support arterial specialization. Also, the mES-EC-PVDF-
TrFE scaffold retained their ability to uptake LDL, a known 
feature of mature endothelial cells (88).
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However, further studies need to be done to determine the 
long-term benefits of in  vitro cultures using PVDF-TrFE scaf-
folds, detailed characterization of its piezoelectric activity, as well 
as its functional integration in vivo (88).
Retrograde Delivery
In the setting of an MI, blood flow to the distal segment will 
be cut off and as such infused stem cells will not be able to get 
to the region of ischemia. In this regard, Wu et al. studied the 
retrograde delivery of cells via the coronary venous vessel which 
was initially described by Baklanov et al. This procedure helps 
to circumvent the blockage to deliver stem cells to the area of 
ischemia. Unlike the delivery of cells into a coronary arterial 
vessel which might trigger an ischemic event, Wu and colleagues 
demonstrated that the temporary blockage of the coronary sinus 
did not result in any hemodynamic change and the procedure 
was well tolerated in the setting of a myocardial injury (50). The 
advantage of this method is in its ability to administer a lot of 
cells, low cost, and less invasive when compared to other delivery 
methods (50).
improved Combinatorial Approach
Though the EPCs have a critical role in the formation of blood 
vessels, the functions of other cells and angiogenic factors can-
not be undermined hence the thought of possible combinations. 
Previous studies have utilized a lot of combinations, but a more 
recent and classic one is the study by Odent and colleagues, 
2015 (89), where they combined the two types of EPC popu-
lations. Two distinct types of EPC exist and are described in 
accordance to how they appear in culture (90, 91). These are 
(1) early outgrowth (EO-EPC), also known as the circulating 
angiogenic cells (CAC) which appear about 7 days in culture. 
The proliferative potentials of EO-EPC have been observed 
to be limited, but with increased secretory activities (89). (2) 
The late outgrowth (LO-EPC), also known as the endothelial 
colony-forming cells (ECFC) are circulating EPCs, which are 
rare and only develop after 2–3  weeks on culture. Both of 
these cells share common EC markers (CD31/PECAM, KDR/
VEGFR2/Flk-1, CD144/VE-Cadherin) and monocyte markers 
(CD14, CD45) (92). Concurrent delivery of ECFC and CAC 
secreting soluble factors has been proven to be of immense ben-
efit for the hind limb ischemia (89). The delivery (i) increases 
the storage of the cells delivered to the area of ischemia, (ii) pulls 
in mural cells to facilitate the stability of the new vessels, and 
(iii) enhances neovascularization and regeneration of muscle 
tissue. The blood from the umbilical cord has been shown to 
possess a higher number of ECFC with a significantly greater 
proliferative potential when compared to cells obtained from 
the adult peripheral circulation (93), hence the justification for 
the use of umbilical cord blood for this study. This combina-
tion demonstrated a better vascular regeneration, and this was 
thought to be due to the first endothelial sprouting followed by 
pericytes ± SMC recruitment. CAC contributed immensely to 
vessel maturation by the secretion of angiogenic and vasculo-
genic factors that promoted survival and proliferation of deliv-
ered cells and organized the intercellular junctions between the 
SMC and ECFC. These factors include VEGF, SDFa (secreted 
in very high amounts in both normoxic and hypoxic states), 
PDGF, Ang2, IL-8, ET-1, MCP-1, 10.
Also, Avolio et  al. also recently combined human pericytes 
SVPs (boosts vascularization) with cardiac stem cells (CSC) 
(promotes cardiomyogenesis) in a mouse MI model (94). This 
combination additively resulted in a scar size reduction with 
increased collateralization. The study showed that both cells 
contributed distinctly rather than cooperatively. SVPs, when 
compared to CSCs, were shown to have a better incorporation 
rate and notably, both cell populations were located far from one 
another in vivo. Particularly, SVPs individually secreted larger 
amounts of angiogenic factors to include microRNAs (miRs)-
132. However, coculture suggested some inhibitory effects where 
these values were significantly reduced in both populations, 
whereas SDF-1α was significantly elevated in the coculture (94). 
Though tissue engineering might be able to harness benefits 
from both cell populations; this, however, has to be carefully 
tailored to consider both the existing competitive and coopera-
tive interactions.
Previous combinations include that of EPCs with smooth 
muscle progenitor cells used in a mice hindlimb ischemia model 
(95). Here, the combination therapy examined the angiogenic 
roles and benefits of Ang-1/Tie2 signaling.
Another recent study combined EPCs with MSCs (a source of 
angiogenic factors and pericyte progenitors) (96). This combina-
tion suggests that bone marrow can potentially generate a vast 
array of chemokines, growth factors, and extracellular matrix 
molecules derived MSCs (97) with molecular and cellular proper-
ties closely similar to that of pericytes (98, 99).
Stem Cells Priming/Pretreatment
Stem Cell Senescence
The senescence of stem cells result in the inability of the cells to 
regenerate injured or ischemic tissues and is thus very detrimen-
tal for the life of the organism. The natural aging process and 
pathologies like diabetes mellitus (DM) contribute to cellular 
senescence. Cellular senescence has been a challenge for thera-
peutic tissue regeneration, and a lot of studies have demonstrated 
that statins, estrogen, high-density lipoprotein, and Insulin-like 
growth factor-1 can trigger the activity of telomerase (100–103). 
Also, hypoxia has been shown to inhibit EPC senescence by 
activating TWIST (104). The priming of stem cells before 
transplantation is a newly emerging technique in overcoming 
senescence in stem cells.
When stem cells become senescent, they undergo a couple of 
changes that include (i) loss of expression of functional markers 
for ECFC such as, CD34, CXCR4 (which is SDF-1a receptor 
and though to delay senescence of subpopulations of EPC), 
VEGFR2, and c-Kit (linked to the recruitment, mobilization 
and survival of EPCs) (105) and (ii) they express low levels 
of SMP30 protein, which is a marker of aging and senescence. 
SMP30 prevent apoptosis in the cells by the inhibition of the 
caspase cascade.
Fucoidan, the sulfated polysaccharide, is a marine product 
extracted majorly from diverse species of brown seaweed and 
brown algae (106). Some functions of Fucoidan have previously 
been itemized such as in combination with FGF-2 have been 
9Fakoya Stem Cells Delivery in Ischemia
Frontiers in Cardiovascular Medicine | www.frontiersin.org February 2017 | Volume 4 | Article 7
shown to enhance the angiogenic activities of EPCs (107), increase 
migration of endothelial cells induced by VEGF165 (108). Lee 
et al. went further to show the effect of Fucoidan on EPC senes-
cence. Which include (i) restoration of the expression of ECFC 
functional markers as described above, and this has been shown 
to be dose-dependent; (ii) prevention of the senescence of ECFC 
via the phosphorylation of Akt, also with increased and decreased 
SMP30 protein and p21 levels, respectively. Akt phosphorylation 
is via the integrin-FAKAkt signaling pathway. Focal adhesion 
kinase (FAK) promotes survival of cells via PI3K/Akt pathway 
(109, 110). This pathway indirectly modulates the expression 
of the cell cycle regulators cyclin-dependent kinases (Cdk2 and 
Cdk4). (iii) Acceleration of senescent ECFC’s proliferation via 
phosphorylation of FAK-ERK, ERK signaling regulates various 
cellular functions, mainly survival and proliferation (111). ERK 
signaling indirectly controls the expression of p21 a Cdk inhibitor 
(cell cycle repressor).
Diabetes can induce a dysfunctional EPC, and microarray 
studies have confirmed this in a homogenous population of 
type 1 DM patients (112). Several studies have shown that 
transplantation of autologous EPCs in the setting of DM foot 
or the utilization of EPCs from patients with DM yielded very 
poor neovascularization. Diabetes results in a significant down-
regulation of a crucial pro-angiogenic glycoprotein Osteopontin 
(OPN). Vaughan et  al. demonstrated that pre-exposure of 
autologous EPCs to OPN might enhance their efficacy before 
transplantation. Thus, dysfunctional EPCs can be induced to 
secrete angiogenic proteins when acted upon in an autocrine 
manner by OPN (112).
Also, Avolio et al. treated senescent CSC gotten from a decom-
pensated heart with rapamycin and resveratrol and these cells 
induced cardiac repair when injected into an infarcted mouse 
heart with the reduction in CMC senescence by reducing the 
secretion of IL1β (113).
miRNA Pretreated Stem Cells
microRNAs, a large family of small non-coding RNAs (22–24 
nucleotides long), they endogenously regulate gene expression 
directly or indirectly and play a vital role in cell proliferation, dif-
ferentiation, and apoptosis (114). The transfection of MSCs with 
specific miRNAs enhanced their survival and their potential for 
lineage differentiation thus potentiating MSCs reparative func-
tion in ischemia.
Mesenchymal stem cells have been transfected with several 
miRNAs such as miR-378 (115), MSC Anti-377 (116), miR-126 
(117). MSCs transfected with mi-R378 compared to the control, 
showed a more rapid proliferation, decreased apoptosis, decreased 
BCL2 levels, upregulated BAX, reduced expression of TNF-α, 
decreased TUSC-2, and formed a higher number of vascular 
branches. Mi-378 transfection also augmented the expression of 
VEGF-α, PDGF-β, and TGF-β1 (115). However, an in vivo study 
of MSC-miR-378 affection is yet to be conducted.
miR-377 binds directly to VEGF and negatively regulates 
its expression (116). Wen et  al  demonstrated a significant 
improvement in myocardial angiogenesis when treated with 
MSCAnti-377, also the degree of fibrosis was observed to be less 
when compared to MSC-null injected cardiac tissue (116).
Huang et  al. demonstrated that MSCs pretreated with miR-
126 encoded in a lentiviral vector survived for a longer period of 
time under hypoxic environment (117). MSC-miR-126 efficiently 
expressed miR-126 for a minimum of 2  weeks at the injected 
site with no demonstrable adverse effects on cell viability. The 
overexpression of miR-126 led to the upregulation of VEGF, 
Notch ligand DII-4, and bFGF in the MSCs. It also improved the 
survival of MSCs and increased functional angiogenesis in the 
ischemic heart tissue. However, the study could not explain how 
the overexpression of miR-126 enhanced the paracrine effects of 
MSCs.
Preconditioning
This approach includes (i) electrical stimulation and (ii) ischemic 
preconditioning both of which has been proven to promote post-
transplantation stem cell survival and improved heart function 
by probably altering exosome contents and functions. It has been 
proposed that the beneficial effects of either approach occur from 
induction of cellular stress (118).
Kim et  al. showed that CSCs preconditioned with electrical 
stimulation demonstrated a decreased apoptosis both in  vitro 
and in vivo by upregulating the pro-survival pathways PI3K/AKT 
and FAK causing the release of connective tissue growth factor 
(CTGF) (119). miR-378 was shown to regulate the expression of 
CTGF. CTGF has known effects on tissue repair, fibrosis, scarring, 
protection against reperfusion injury, ES adhesion and survival. 
Also, CTGF has been shown to bind to a number of growth 
factors and mediators that direct a variety of cellular pathways 
(119). However, their study did not explore the impact of electri-
cal stimulation on exosomes as well as the cytoprotective effects 
of electrical stimulation.
Ischemic preconditioning is a process where cells are exposed 
to repeated cycles of anoxia with intermittent re-oxygenation. 
Kim and colleagues, in a study of ischemic preconditioning, 
demonstrated an intracellular increase in the levels of miR-210. 
The expression of this miRNA resulted in the activation of 
the AKT/ERK1/2 survivals pathways targeting the Caspase-8-
assoicated protein 2, an initiator of apoptosis (119). A recent 
study by Feng et al., not only demonstrated the expression and 
loading of the antiapoptotic miR-22 in exosomes but was able 
to capture the dynamic intracellular course of exosomes and the 
extracellular shedding of miRNA-loaded exosomes. miRNA-22 
reduced apoptosis in ischemic CMCs by directly targeting methyl 
binding protein 2, ameliorated fibrosis, and enhanced cardiac 
function (120).
The window of protection offered by electrical stimula-
tion is shorter when compared to ischemic preconditioning, 
and this further supports their different molecular signaling 
pathways  (117).
Stem Cell exosomes
Stem cells demonstrably secrete paracrine factors not only 
in naked forms but also membrane bound vesicles such as 
exosomes among others (121). Exosomes are secreted vesicles, 
30–100 nm in diameter and are also referred to as extracellular 
vesicles. They are essentially composed of a host of biologically 
active molecules, such as messenger RNAs (mRNAs), miRs, and 
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proteins (122). Exosome formation is initiated from the invagi-
nation of the endosomal membrane that results in the forma-
tion of intraluminal vesicles or multivesicular bodies (MVBs), 
which in the process accumulate cytoplasmic molecules such as 
mRNAs, miRs, and proteins (123). The ILVs/MVBs fuse with the 
plasma membrane and are released into the extracellular envi-
ronment by exocytosis as exosomes. MVB formation has been 
reported to be mediated by the endosomal sorting complexes 
required for transport (ESCRT) and other ESCRT independent 
machinery (124). The other molecules involved in the exosome 
formation are the tetraspanins (CD9, CD63, and CD81) which 
are expressed on exosomes and can be used as exosome identity 
markers (121).
Exosomes isolated from different types of stem cells such as 
MSCs, iPSCs, cardiac progenitor cells, ESCs, and CD34+ have 
been utilized in the study of cardiac and limb ischemia. In these 
studies, exosomes were shown to significantly suppress apoptosis 
(120, 125–127), stimulate angiogenesis (125, 127–131), reduce 
infarct size (128, 132, 133), and recover cardiac function (125, 
127, 128, 131–133). Also, they have been shown to be enriched in 
miRs such as miR-22 (120), miR-19a (133), miR-133b (134), miR-
146a (125), miR-294 (131), and sonic hedgehog, a pro-angiogenic 
factor (135).
Despite the demonstrable angiogenic benefits of exosomes for 
CMC regeneration after an acute MI, MSC-derived exosomes 
have also been shown to promote tumorigenesis in  vivo by 
stimulating VEGF in tumor cells (136). Therefore, a technique 
to specifically deliver the exosomes to target tissues needs to be 
explored.
Magnetically Targeted Delivery  
of Stem Cells
This study involves the use of biocompatible nanoparticles that 
are magnetically responsive for the targeted transplantation 
of stem cells so as to facilitate their retention in the region of 
therapeutic interest. Furthermore, these nanoparticles can be 
utilized for tracking and monitoring of cells in vivo with the use 
of magnetic resonance imaging.
Magnetic Nanoparticles
The superparamagnetic iron oxide nanoparticles are typically 
made up of a core of magnetite or maghemite which are both 
naturally ferromagnets, but at specific radii, they become super-
paramagnets (137). Superparamagnet iron oxide NPs (SPIONs) 
can broadly be categorized by their size, which is relevant to the 
field of study as well as their application. These include the very 
small superparamagnetic iron oxide NPs, less than 10 nm; ultra-
small superparamagnet iron oxide NPs, 10–50 nm; and lastly the 
SPIONs, 50–180  nm, which are employed in the field of stem 
cells (137).
Stem Cell Tagging with SPIONs
Stem cells are tagged with the nanoparticles using any of 
these methods: (i) passive diffusion, (ii) phagocytosis, and 
(iii) endocytosis, which can be macropinocytosis, clathrin, 
or caveolae-mediated endocytosis and other variants that are 
independent of clathrin or caveolae (138). However, mostly 
utilized is the endocytosis, in which the cells are incubated 
for about 12–48  h (139). Below, in Figure  4, is a schematic 
summary.
Delivery of Stem Cells Tagged with SPIONs
Several studies have utilized the SPION-tagged stem cells in 
vascular injury. Kyrtatos and colleagues used CD133+ EPCs, and 
they targeted these tagged cells using a magnetic device at the site 
of catheterization in the common carotid artery of a rat hoping to 
prevent re-obstruction post angioplasty. The engrafted CD133+ 
tagged cells to the area of injury had 5.4-factor increase about the 
control. The SPION technique has also been used in heart models 
to overcome the “Washout” or “displacement” of stem cells during 
cardiac contraction or coronary blood flow (140). Vandergriff and 
colleagues, in their study, used Feraheme, coupled with heparin 
(H) and protamine (P) sulfates forming complexes of FHP (139), 
and then incubated the cardiospheres with these complexes. The 
tagged cardiospheres experimented on a rat ischemic heart model 
with a magnetic field applied. Exposure to the magnet increased 
the rate of cell retention by three folds about the control. Also, 
there was no remarkable inflammatory difference (CD68 marker 
used) about control demonstrating its safety with improvement 
in cardiac morphology, remodeling, and scar attenuation.
Other areas to be considered in this delivery method include 
(i) the number of cells (dose), (ii) the magnetic intensities, (iii) 
duration of the application of the magnet, and (iv) cell size. Cheng, 
in his study in 2012 (141), in a rat ischemic heart model injected 
iron microsphere labeled cells derived from cardiospheres into 
the left anterior coronary artery and a 1.3 T magnet placed 1 cm 
above the heart. The 24-h cell retention was enhanced by a factor 
of 5.2–6.4 about control. They also demonstrated that the infu-
sion of 1 × 105, 3 × 105, or 5 × 105 cells resulted in no elevation of 
serum troponin levels, but higher cell number (1/2 × 106) raised 
troponin levels with no improvement in cell retention. This effect 
was attributed to microvascular obstruction (141).
After that, Shen et al. compared the effect of different magnetic 
intensities for MSC targeting for myocardial ischemic repair. The 
left ventricle was injected with SPION-tagged 1 × 106 MSCs with 
the application of magnetic intensities of 0.15, 0.3, and 0.6  T 
(142). This study showed a magnetic dose-dependent increase 
in cell retention, but at 0.6  T, there was no significant thera-
peutic outcome as MSC engraftment was confirmed to be low. 
Microembolism was linked to the therapeutic outcome observed 
at the too high magnetic strength (142). However, a different study 
affirmed that the cell dosage (1 × 106) could also result in micro 
embolism regardless of magnetic intensity (141). So far, 10 min 
have been utilized for the magnet application, time. However, this 
is yet to be fully optimized (141) and also the smaller cells might 
less likely result in micro embolisms, so embryonic-like (2–4 μm) 
stem cells have to be looked into Ref. (142).
For its application in humans, Cheng and Vandergriff et  al. 
proposed the schematic below in Figure 5.
US in Stem Cell Delivery
Ultrasound is another novel method of stem cell delivery 
where acoustic force is used to enhance delivery of stem cells 
FiGURe 5 | Delivery of stem cells tagged with SPiONs.
FiGURe 4 | Schematic overview of tagging stem cells with SPiONs.
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to target sites. There are currently two approaches: (i) the US 
ability to displace cells toward the target site and (ii) the US 
directed modification of the target site microenvironment. The 
US delivery systems utilize microbubbles for its function. The 
first description of the delivery of stem cells using US radiation 
was by Toma et al. and was based on the intravascular catheter 
displacement of MSCs coated with gas filled, lipid-shelled 
microbubbles (143). The schema in Figure  6 demonstrates its 
possible design in humans.
The attachment of the microbubbles to the surface was 
catatonically enhanced, and microbubble number of about 
7–11 facilitated the greatest adhesion of MSCs (143). However, 
FiGURe 6 | US enhanced delivery of stem cells bound microbubbles.
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increasing microbubble coating resulted in a corresponding 
decrease in adhesion of cells, and this effect was attributed to 
physical interference by the microbubbles (143). The target site 
MSC enrichment was outstanding being up to a factor of 150 
when compared to the SPIONs loaded EPC which yielded only 
a target site enrichment of a factor of 6 over control (141). The 
extended exposure to the microbubbles, however, resulted in a 
5% excess MSC death more than control. In all, the cell type and 
the catheter used for this delivery will still require further studies.
The other approach is the alteration of the microenviron-
ment of the target site by “US-targeted microbubble destruction” 
(UTMD). Ling et al. used this system in dog model 1 week after 
the MI, where a 1 MHz transducer with a 2 cm diameter was used 
to irradiate the left ventricular wall after the femoral vein was 
injected with 2 ml of microbubbles for 10 min (144). The UTMD 
can enhance permeability and rupture of the microvasculature 
(145) and also promote angiogenesis by stimulating the secretion 
of endogenous angiogenic growth factors (146, 147). The irradi-
ated site resulted in some modification of the microenvironment, 
which stimulated some inflammatory response that was useful 
for mobilizing stem cells (144). However, excessive infiltration 
of inflammatory cells may induce apoptosis or necrosis (148). 
UTMD demonstrably improved angiogenesis, collateral coronary 
circulation, and myocardial perfusion (144).
The probable mechanism may be that the capillary rupture 
and the endothelial widening promoted the stem cell attachment 
to the damaged endothelial layer with cytokine release further 
enhancing the homing process of the cells (144). The side effects 
documented for this procedure include necrosis or apoptosis of 
CMCs, arrhythmias, extensive destruction of the endothelium, 
and leakage of micro-vessels.
New Homing enhancing Technique
Several studies have reported that transplanted EPCs home to 
regions of ischemic injury (62, 149). However, the precise homing 
mechanisms are not completely understood; however, playing a 
central role is the interaction between molecules on the surface 
of EPCs and upregulated ligands at the site of injury. Recently, 
Heo et  al. (150) showed that homing of transplanted human 
EPCs and vascular repair was promoted by repeated injections 
of WKYMVm a synthetic peptide (a chemoattractant for human 
phagocytes) into ischemic limbs, this subsequently activated 
formyl peptide receptor 2 (FPR2) on EPCs. EPCs begin to 
express FPR2 and FPR3 from day 7 to 10 in culture. The binding 
of WKYMVm to FPR2 induces the proliferating, migrating, and 
sprouting activities of EPCs (150).
Stem Cell Modulation
The hunt for the best ways to improve the delivery of stem cells to 
areas of ischemia appears unending as the fields of immunology, 
molecular biology, genetic, and proteomics also have their part 
to contribute. Leading the wave are (i) antibody, (ii) genetic, (iii) 
selectin, and (iv) peptide-directed approaches  (151).
Antibodies
These involve two strategies: (i) the use of Palmitate protein-G or 
A to attach antibodies to the surfaces of cells including stem cells 
and (ii) the use of antibodies that are “bispecific” having affinities 
TABLe 2 | Markers of classical (M1) and alternative (M2) activation.
Classical (M1) Alternative (M2)
Pro-inflammatory Anti-inflammatory
Fas ligand high Arginase I/II
Interferon γ high CD 163
Interleukin-1β high Fas ligand low
Interleukin-6 high Basic fibroblast growth factor (FGF)
Interleukin-8 high Interferon γ low
Interleukin-10 high Interleukin-4 receptor I
Interleukin-12 high Interleukin-6 low
Interleukin-23 high Interleukin-10 high
Matrix metalloproteinases Interleukin-12 low
Nitric oxide (NO) Interleukin-23 low
Extracellular matrix destruction Extracellular matrix reconstruction
Inducible NO synthase MS-1-high molecular weight protein
Tumor necrosis factor α high Transforming growth factor β
Tumor necrosis factor low
Vascular endothelial growth factor
Adapted from Ref. (165).
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for the cell to be delivered and the region of interest. However, the 
use of protein-G is more favored as the production of bispecific 
antibodies could be challenging and have shown some instabil-
ity. HSCs have been targeted to an injured cardiac vessel using 
bispecific antibodies; these were done using either anti-c-kit 
conjugated to anti-VCAM (152), anti-myosin light chain kinase, 
or anti-CD45 (153).
Genetic Manipulation
This is where DNA or RNA is introduced into a cell to aid the 
expression of ligands on the surface of the cell to enhance homing 
and attachment to tissue of interest. Increased homing of MSCs 
transduced with CXCR4 toward an infarcted heart was found 
to improve cardiac output and angiogenesis within an infarcted 
heart (154, 155). This method though seems lucrative, but the 
possibility of its translation for clinical use is certainly daunting.
Selectin
This approach is designed to mimic the natural immunity of the 
body. Sackstein et  al. (156) modified the “selectin-directed cell 
targeting” pioneered by Xia et al. (157) to modify the surface of 
MSCs forming HCELL, which is a ligand that binds to E-selectin 
and L-selectin. Stem cells coated with selectin-binding ligands 
penetrated through the EC and the layers of the basement mem-
brane to migrate to the area of pathology from the circulation.
Peptide Directed
Here, stem cells coated with targeting peptides were identified by 
phage display, the technique was pioneered partly by Kean et al. 
(151). Tissue or cell ligands can be highly specific, and the cell 
surfaces targeted with multiple ligands. However, it appears no 
peptide-targeted therapeutic agent has made it to the market yet 
about the antibody-based one (158).
Mannitol-enhanced Delivery
Adult and neonatal ischemic injury to the brain is quite a 
clinically significant problem with the paucity of therapeutic 
interventions. For clinicians at present, the treatment of stroke 
patients is limited to the use of tPA (159). Stem cell therapy 
in the brain in small clinical trials has proven to be effective 
but, however, is limited by their delivery into the injured brain 
as the brain is protected by a Blood–Brain Barrier (BBB). 
Surgical delivery though very useful, but it is invasive and is 
accompanied by its own complications (160). Thus, a minimally 
invasive approach is more favored. Hence, strategies have been 
designed to fragment the BBB for the delivered cells to gain 
entry into the brain substance (159). Gonzales-Portillo et  al. 
did a study et al. which demonstrated that mannitol a substance 
that transiently opens the BBB-facilitated delivery of stem cells 
and trophic factors into the brain (159) thus, stem cell therapy 
combined with mannitol may enhance therapeutic results in 
adult stroke patients. The use of stem cells in cerebral ischemia 
has recorded several successes (161, 162), and their combination 
with mannitol might prove lucrative in the management of stroke 
patients. However, considering the critical function of the BBB, 
permeating it might allow harmful or inflammatory chemokines 
or cytokines to breach the barrier and worsen the pathologic 
site. Therefore, the use of this technique will put into critical 
consideration the period of permeation and the size of the leakage 
for selective passage of stem cells and growth factors.
FUTURe wORK: COMBiNeD DeLiveRY 
OF MACROPHAGeS AND STeM CeLLS
The process of ischemia results in tissue apoptosis and necrosis 
which triggers the cleaning up process, angiogenesis, and 
remodeling. Macrophages have been shown to play an enor-
mous function during apoptosis and necrosis, tissue clean up, 
repair or remodeling, and angiogenesis in any ischemic event. 
The increased post-MI myocardial rupture and mortality 
in subjects who had their immune system suppressed with 
methylprednisolone in early clinical trials confirmed the deci-
sive role of the inflammatory process influenced primarily by 
macrophages (163, 164).
The role of macrophages post-ischemic event is critical as it is 
considered a key player in the post-ischemic regenerative process. 
Thus, its therapeutic potentials need to be regarded as strongly 
not just alone as confirmed by the first administration of polar-
ized macrophages by Jetten et al. (39) but possibly in combination 
with other stem cells for a better therapeutic effect.
Activation of macrophages usually occurs on day 3 post-
ischemia, and the two main patterns of activation include M1 
(classical), activated by LPS or γ-IFN (interferon), and M2 
(alternative), which has two subsets M2a and M2c activated by 
IL-4 and IL-10, respectively. M1 is pro-inflammatory, while M2 
is anti-inflammatory (165). See Table 2 below for the summary 
of secretions.
Furthermore, macrophage cultures have yielded over 150 
secretory proteins secreted by macrophages, and some of these 
proteins are either pro-angiogenic or angiostatic helping to regu-
late the angiogenic process tightly. In Table 3 is a few of the key 
secretory proteins of the macrophage.
A number of macrophages in different injury models such 
as MI, PAD, stroke, and wound healing have been shown to 
TABLe 3 | A few key secretory proteins of macrophages.
Cytokines and chemokines Growth factors
α-2 macroglobulin Angiotensinogen
ADAMTS-4, -7, -8, -9 Basic FGF
Angiotensin converting enzyme Endothelial cell inhibitory factor
Caspases 2, 3, 8, 9
Cathepsin B
Interferon α
Interleukin-1 α and β, -6, -8, -10
Macrophage inflammatory proteins
MMP-1, -3, -7, -8, -9, -12
Monocyte chemotactic protein-1
Plasmin
Plasminogen activator inhibitor 1
Proteases and protease inhibitors
Tumor necrosis factor α
Granulocyte colony stimulating 
factor
Granulocyte-macrophage colony 
stimulating factor
Insulin-like Growth Factor 1
Macrophage colony stimulating 
factor
Monocyte chemotactic protein-1
Substance-P
Thrombospondin-1
Transforming growth factors α and β
Vascular endothelial growth factor
Adapted from Ref. (165).
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correlate positively with angiogenesis (166). Macrophages can 
influence every step of the angiogenic process such as local 
ECM modification, EC induction to migrate or proliferate, 
and vascular growth inhibition, once capillaries have been 
formed (165).
Macrophages induce angiogenesis by expressing MMPs, which 
disintegrates the basement membrane and degrades the ECM of 
the capillary, thus facilitating migration of the endothelial cells. 
Macrophages initially drill a tunnel in the matrix, which is then 
colonized by either EPCs or capillary sprouts (165). Several 
MMPs are synthesized by macrophages such as: MMP-1, -3, -7, 
-8, -9, and -12. However, MMP-9 appears to be most relevant 
to post-ischemic remodeling, and this is elaborately expressed 
during the differentiation of macrophages and overexpressed 
after an ischemic event (167). Macrophages also release (TIMPs) 
which functions to inhibit MMPs as well regulating cell growth 
and signaling (168).
FiGURe 7 | Delivery of Polarized macrophages with potentiated stem cells.
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The fact that tissue ischemia results in reduced blood flow 
limit the number of monocytes that are available to differenti-
ate into macrophages at the region of ischemia, hence the 
benefit of the exogenously delivered polarized macrophages. 
Jetten et  al. demonstrated that both M1 and M2 macrophages 
act in a complementary manner to stimulate arteriogenesis. 
M1 pro-angiogenic factors, TNF-α and iNOS, and M2-FGF-2 
worked in concert with other macrophage-derived growth fac-
tors and cytokines during vascular remodeling. Whereas, the 
non-polarized macrophages did not demonstrate any collateral 
flow. A possible downside to macrophage delivery might be tissue 
inflammation; however, there was no documentation of this in the 
study of Jetten and colleagues. This might be due to the number 
of the macrophages delivered in the study or the opposing effect 
of the anti-inflammatory M2 cytokines TGF-B and IL-10 on M1. 
Hence, further studies might be required to investigate possible 
tissue inflammation.
Since the goal of delivering stem cells is to achieve the most 
efficient vascular and tissue regeneration, the tissue reparative 
role of the macrophage, however, impressive, might not be suffi-
cient. Therefore, studies might be designed to harness the possible 
synergistic benefits of combining polarized macrophages with 
potentiated stem cells and delivered in the most efficient way to 
the region of ischemia. See Figure 7 below.
CONCLUSiON
This study reviewed quite a variety of available new methods of 
delivering stem cells. A number of these new methods minimized 
the invasiveness of delivering stem cells to the subject. These 
delivery methods resulted in improved retention, survival, and 
engraftment of these cells and led to remarkable improvements 
in angiogenesis, collateral vessel formation, improved tissue 
perfusion, and ultimately salvaged and significantly restored 
tissue function. Though these studies yielded good success rates 
in animal models, they however still require extensive studies 
for translation into humans. The study also proposed possible 
synergistic benefits that might exist in the efficient delivery of a 
combination therapy of polarized macrophages with stem cells 
as this might enhance not only angiogenesis but an efficiently 
regenerated tissue.
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